SCHEMBL4416042

SCHEMBL4416042

CSc1ccc(-c2noc(CCOC3CN(C(=O)OC(C)(C)C)C3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.52
HDAC4 P56524 4/20 0.43
HDAC6 Q9UBN7 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 4/20 0.40
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TP53 P04637 3/20 0.39
KLF5 Q13887 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NAMPT P43490 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414284 0.91 GPR119 (0.64) GPR119HDAC4HDAC6SMN1; SMN2MAPT
SCHEMBL4411714 0.86 GPR119 (0.51) GPR119HDAC4
SCHEMBL4412913 0.85 GPR119 (0.51) GPR119HDAC4HDAC6SMN1; SMN2MAPT
SCHEMBL4414146 0.82 GPR119 (0.58) GPR119HDAC4HDAC6SMN1; SMN2MAPT
SCHEMBL4413000 0.81 GPR119 (0.52) GPR119HDAC4HDAC6SMN1; SMN2MAPT
SCHEMBL4416063 0.81 GPR119 (0.78) GPR119HDAC4HDAC6SMN1; SMN2RAB9A
SCHEMBL4412914 0.79 GPR119 (0.46) GPR119HDAC4HDAC6HDAC1HDAC8
SCHEMBL12603064 0.79 GPR119 (0.82) GPR119HDAC4HDAC6SMN1; SMN2LMNA
SCHEMBL4425890 0.78 GPR119 (0.58) GPR119HDAC4HDAC6LMNAHPGD
SCHEMBL4423369 0.77 GPR119 (0.62) GPR119HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885HDAC4 2550/4885HDAC6 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.